CD274 and esophageal squamous cell carcinoma: Whereas, overall survival of patients was significantly longer in the pembrolizumab group no matter TPS ≥ 50%, 20%, or 1%.226 While in another phase III trial comparing the pembrolizumab effect in advanced ESCC, patients were enroled regardless of PD-L1 status.